Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) were down 5.6% during mid-day trading on Wednesday . The company traded as low as $13.04 and last traded at $13.40. Approximately 1,350,118 shares traded hands during mid-day trading, an increase of 82% from the average daily volume of 742,836 shares. The stock had previously closed at $14.20.

A number of analysts have issued reports on ABEO shares. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a report on Friday, May 12th. Maxim Group set a $14.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Saturday, May 13th. FBR & Co reissued a “buy” rating on shares of Abeona Therapeutics in a report on Friday, May 26th. Jefferies Group LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Abeona Therapeutics in a report on Thursday, June 1st. Finally, Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $17.86.

The firm has a 50 day moving average price of $9.13 and a 200 day moving average price of $6.54. The stock’s market capitalization is $539.85 million.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.07. The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.21 million. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. On average, analysts forecast that Abeona Therapeutics Inc. will post ($0.67) earnings per share for the current year.

Large investors have recently modified their holdings of the stock. Private Advisor Group LLC grew its stake in Abeona Therapeutics by 50.0% during the first quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 6,999 shares in the last quarter. Family Management Corp purchased a new position in Abeona Therapeutics during the first quarter valued at approximately $120,000. State of Wisconsin Investment Board purchased a new position in Abeona Therapeutics during the second quarter valued at approximately $122,000. Segantii Capital Management Ltd grew its stake in Abeona Therapeutics by 564.6% during the first quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock valued at $169,000 after acquiring an additional 28,794 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in Abeona Therapeutics during the second quarter valued at approximately $190,000. 38.24% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Abeona Therapeutics Inc. (ABEO) Shares Down 5.6%” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/06/abeona-therapeutics-inc-abeo-shares-down-5-6.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).